Back to search

Article

Multimetric MRI Captures Early Response and Acquired Resistance of Pancreatic Cancer to KRAS Inhibitor Therapy

2024-11-25

Abstract excerpt

<h4>Purpose</h4> In pancreatic ductal adenocarcinoma (PDAC), KRAS mutations drive both cancer cell growth and formation of a dense stroma. Small molecule KRAS inhibitors (KRASi) represent a promising new treatment hence clinical tools that can assess early response, detect resistance and/or predict prolonged survival are desirable to understand clinical biology of KRASi. We hypothesized that diffusion-weighted MR...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5a569fc4-d3c5-5bbd-aefe-96d1c07767ea
DOI
10.1101/2024.11.22.624844
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Multimetric MRI Captures Early Response and Acquired Resistance of Pancreatic Cancer to KRAS Inhibitor TherapyDOI 10.1101/2024.11.22.624844
Evaluation of tumour perfusion and fibrosis in mouse models of pancreatic ductal adenocarcinoma, using MRISemantic proximity
Effect of Stroma-directed Drugs in Combination with Chemotherapy Against Pancreatic Cancer- a Preclinical StudySemantic proximity
Spatial Biology and Organoid Technologies Reveal a Potential Therapy-Resistant Cancer Stem Cell Population in Pancreatic Ductal AdenocarcinomaSemantic proximity
CDK8 remodels the tumor microenvironment and promotes resistance to KRASG12D inhibitors and daraxonrasib in PDAC.Semantic proximity
Oncogenic Kras <sup>G12D</sup> specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 <sup>+</sup> T cells dependent mannerSemantic proximity
Correlation of MRI characteristics with KRAS mutation status in pancreatic ductal adenocarcinoma.Semantic proximity
Pharmacologically targeting KRAS <sup>G12D</sup> in PDAC models: tumor cell intrinsic and extrinsic impactSemantic proximity
Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.Semantic proximity
The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer.Semantic proximity
Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy responseSemantic proximity
Defining and targeting adaptations to oncogenic KRAS <sup>G12C</sup> inhibition using quantitative temporal proteomicsSemantic proximity
An engineered pancreatic cancer model with intra-tumoral heterogeneity of driver mutations.Semantic proximity
Select a neighboring publication to make it the new centre.